Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2022

Open Access 01-12-2022 | Panic Disorder | Study protocol

Self-guided digital treatment with virtual reality for panic disorder and agoraphobia: a study protocol for a randomized controlled trial

Authors: Jari Planert, Alla Machulska, Anne-Sophie Hildebrand, Kati Roesmann, Esra Otto, Tim Klucken

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Cognitive behavioral therapy is the first-line treatment for patients with panic disorder (PD) and agoraphobia (AG). Yet, many patients remain untreated due to limited treatment resources. Digital self-guided short-term treatment applications may help to overcome this issue. While some therapeutic applications are already supported by health insurance companies, data on their efficacy is limited. The current study investigates the effect of self-guided digital treatment comprising psychoeducation and virtual reality exposure therapy (VRET).

Methods

Thirty patients diagnosed with PD, AG, or panic disorder with agoraphobia (PDA) will be randomly assigned to either the experimental group (EG) or the control group (CG). Participants of both groups will undergo baseline diagnostics in the first two sessions. The subsequent treatment for the EG consists of a self-guided 6-week phase of application-based psychoeducation, one therapy session preparing for the VRET, and 4 weeks of application-based self-guided VRET. To control for the potential effects of the therapy session with the therapist, the CG will receive relaxation and stress-reduction training instead. All patients will then undergo a closing session which terminates with the post-assessment (~ 10 weeks after baseline assessment) and a follow-up assessment 6 weeks following the closing session. Symptom severity (primary outcome) will be assessed at baseline, interim, post-treatment, and follow-up. Additionally, remission status (secondary outcome) will be obtained at follow-up. Both measures will be compared between the groups.

Discussion

The current study aims at providing insights into the efficacy of short-term treatment applications including psychoeducation and self-guided VRET. If successful, this approach might be a feasible and promising way to ease the burden of PD, AG, and PDA on the public health system and contribute to a faster access to treatment.

Trial registration

ISRCTN ISRCTN10661970. Prospectively registered on 17 January 2022.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Craske MG, Barlow DH. Clinical handbook of psychological disorders: a step-by-step treatment manual. 5th ed. New York: Guilford Publications; 2014.
4.
5.
Dilling H, Freyberger HJ, Cooper JE. Taschenführer zur ICD-10-Klassifikation psychischer Störungen. Bern: Hogrefe; 2016.
6.
Balaram K, Marwaha R, editors. Agoraphobia. Treasure Island: StatPearls Publishing; 2021.
7.
Goisman RM, Warshaw MG, Peterson LG, Rogers MP, Cuneo P, Hunt MF, et al. Panic, agoraphobia, and panic disorder with agoraphobia: data from a multicenter anxiety disorders study. J Nerv Ment Dis. 1994;182:72–9.PubMedCrossRef
8.
Perugi G, Frare F, Toni C. Diagnosis and treatment of agoraphobia with panic disorder. CNS Drugs. 2007;21:741–64.PubMedCrossRef
9.
Salkovskis PM, Clark DM, Hackmann A, Wells A, Gelder MG. An experimental investigation of the role of safety-seeking behaviours in the maintenance of panic disorder with agoraphobia. Behav Res Ther. 1999;37:559–74.PubMedCrossRef
10.
Wittchen H-U, Gloster AT, Beesdo-Baum K, Fava GA, Craske MG. Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010;27:113–33.PubMedCrossRef
11.
Uhde TW, Roy-Byrne PP, Vittone BJ, Boulenger J-P, Post RM. Phenomenology and neurobiology of panic disorder. In: Anxiety and the anxiety disorders. London: Routledge; 2019. p. 557–76.
12.
Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disorder: efficacy and strategies. J Clin Psychiatry. 2005;66:28–32.PubMed
13.
Sánchez-Meca J, Rosa-Alcázar AI, Marín-Martínez F, Gómez-Conesa A. Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clin Psychol Rev. 2010;30:37–50.PubMedCrossRef
14.
Meuret AE, Wolitzky-Taylor KB, Twohig MP, Craske MG. Coping skills and exposure therapy in panic disorder and agoraphobia: latest advances and future directions. Behav Ther. 2012;43:271–84.PubMedCrossRef
15.
Arntz A. Cognitive therapy versus interoceptive exposure as treatment of panic disorder without agoraphobia. Behav Res Ther. 2002;40:325–41.PubMedCrossRef
16.
Brettschneider C, Bleibler F, Hiller TS, Konnopka A, Breitbart J, Margraf J, et al. The allocation of resources in the care for patients with panic disorder in Germany: an excess cost analysis informing policy and science. Cost Effective Resourc Allocation. 2019;17:1–11.CrossRef
17.
Cavanagh K. Geographic inequity in the availability of cognitive behavioural therapy in England and Wales: a 10-year update. Behav Cogn Psychother. 2013;42:497–501.PubMedCrossRef
18.
Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Arch Gen Psychiatry. 1989;46:984–92.PubMedCrossRef
19.
Wilson CJ, Rickwood DJ, Bushnell JA, Caputi P, Thomas SJ. The effects of need for autonomy and preference for seeking help from informal sources on emerging adults’ intentions to access mental health services for common mental disorders and suicidal thoughts. Adv Ment Health. 2011;10:29–38.CrossRef
20.
21.
Schmidt NB, Telch MJ. Nonpsychiatric medical comorbidity, health perceptions, and treatment outcome in patients with panic disorder. Health Psychol. 1997;16:114.PubMedCrossRef
22.
Machulska A, Eiler TJ, Kleinke K, Grünewald A, Brück R, Jahn K, et al. Approach bias retraining through virtual reality in smokers willing to quit smoking: a randomized-controlled study. Behav Res Ther. 2021;141:103858.PubMedCrossRef
23.
Botella C, García-Palacios A, Villa H, Baños RM, Quero S, Alcañiz M, et al. Virtual reality exposure in the treatment of panic disorder and agoraphobia: a controlled study. Clin Psychol Psychother. 2007;14:164–75.CrossRef
24.
Donker T, Petrie K, Proudfoot J, Clarke J, Birch M-R, Christensen H. Smartphones for smarter delivery of mental health programs: a systematic review. J Med Internet Res. 2013;15:e2791.CrossRef
25.
26.
Cavanagh K, Shapiro D, van den Berg S, Swain S, Barkham M, Proudfoot J. The effectiveness of computerized cognitive behavioural therapy in routine care. Br J Clin Psychol. 2006;45:499–514.PubMedCrossRef
27.
Learmonth D, Trosh J, Rai S, Sewell J, Cavanagh K. The role of computer-aided psychotherapy within an NHS CBT specialist service. Counsel Psychother Res. 2008;8:117–23.CrossRef
28.
Firth J, Torous J, Carney R, Newby J, Cosco TD, Christensen H, et al. Digital technologies in the treatment of anxiety: recent innovations and future directions. Curr Psychiatry Rep. 2018;20:1–8.CrossRef
29.
Carl E, Stein AT, Levihn-Coon A, Pogue JR, Rothbaum B, Emmelkamp P, et al. Virtual reality exposure therapy for anxiety and related disorders: a meta-analysis of randomized controlled trials. J Anxiety Disord. 2019;61:27–36.PubMedCrossRef
30.
Peñate W, Pitti CT, Bethencourt JM, La Fuente J, de, Gracia R. The effects of a treatment based on the use of virtual reality exposure and cognitive-behavioral therapy applied to patients with agoraphobia. Int J Clin Health Psychol. 2008;8:5–22.
31.
32.
Sars D, van Minnen A. On the use of exposure therapy in the treatment of anxiety disorders: a survey among cognitive behavioural therapists in the Netherlands. BMC Psychol. 2015;3:1–10.CrossRef
33.
Gromer D, Madeira O, Gast P, Nehfischer M, Jost M, Müller M, et al. Height simulation in a virtual reality CAVE system: validity of fear responses and effects of an immersion manipulation. Front Hum Neurosci. 2018;12:372.PubMedPubMedCentralCrossRef
34.
Mühlberger A, Pauli P. Virtuelle realität in der psychotherapie. PiD-Psychother Dialog. 2011;12:143–7.CrossRef
35.
Wechsler TF, Kümpers F, Mühlberger A. Inferiority or even superiority of virtual reality exposure therapy in phobias?—a systematic review and quantitative meta-analysis on randomized controlled trials specifically comparing the efficacy of virtual reality exposure to gold standard in vivo exposure in agoraphobia, specific phobia, and social phobia. Front Psychol. 2019;10:1758.PubMedPubMedCentralCrossRef
36.
Ghosh A, Marks IM. Self-treatment of agoraphobia by exposure. Behav Ther. 1987;18:3–16.CrossRef
37.
Nolet K, Corno G, Bouchard S. The adoption of new treatment modalities by health professionals and the relative weight of empirical evidence in favor of virtual reality exposure versus mindfulness in the treatment of anxiety disorders. Front Hum Neurosci. 2020;14:86.PubMedPubMedCentralCrossRef
38.
Angern J, Angern C, Reineke B. Invirto. Hamburg: Sympatient; 2021.
39.
Faul F, Erdfelder E, Lang A-G, Buchner A. G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175–91.PubMedCrossRef
40.
Titov N, Dear BF, Johnston L, Lorian C, Zou J, Wootton B, et al. Improving adherence and clinical outcomes in self-guided internet treatment for anxiety and depression: randomised controlled trial. PLoS One. 2013;8:e62873.PubMedPubMedCentralCrossRef
41.
Titov N, Dear BF, Staples LG, Terides MD, Karin E, Sheehan J, et al. Disorder-specific versus transdiagnostic and clinician-guided versus self-guided treatment for major depressive disorder and comorbid anxiety disorders: a randomized controlled trial. J Anxiety Disord. 2015;35:88–102.PubMedCrossRef
42.
Benbow AA, Anderson PL. A meta-analytic examination of attrition in virtual reality exposure therapy for anxiety disorders. J Anxiety Disord. 2019;61:18–26.PubMedCrossRef
43.
Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7.PubMedPubMedCentralCrossRef
44.
Cuijpers P, Schuurmans J. Self-help interventions for anxiety disorders: an overview. Curr Psychiatry Rep. 2007;9:284–90.PubMedCrossRef
45.
Melo M, Vasconcelos-Raposo J, Bessa M. Presence and cybersickness in immersive content: effects of content type, exposure time and gender. Comput Graphics. 2018;71:159–65.CrossRef
46.
Singla A, Fremerey S, Robitza W, Raake A. Measuring and comparing QoE and simulator sickness of omnidirectional videos in different head mounted displays. Ninth International Conference on Quality of Multimedia Experience; 2017.
47.
Adler CM, Craske MG, Barlow DH. Relaxation-induced panic (RIP): when resting isn’t peaceful. Integr Psychiatry. 1987;5:94–100.
48.
Bandelow B, Hajak G, Holzrichter S, Kunert HJ, Rüther E. Assessing the efficacy of treatments for panic disorder and agoraphobia: I. Methodological problems. Int Clin Psychopharmacol. 1995;10:73–81.PubMedCrossRef
49.
Margraf J. Entstehung und Handhabung des Mini-DIPS. In: Margraf J, editor. Mini-DIPS. Heidelberg: Springer; 1994. p. 21–36.
50.
Stein J, Luppa M. Allgemeine Depressionsskala (ADS). Psychiatr Prax. 2012;39:302–4.CrossRef
51.
Lukat J, Margraf J, Lutz R, van der Veld WM, Becker ES. Psychometric Properties of the Positive Mental Health Scale (PMH-scale). BMC Psychol. 2016;4:1–14.CrossRef
52.
Hasler G, Klaghofer R, Buddeberg C. The University of Rhode Island Change Assessment Scale (URICA). Psychother Psychosom Med Psychol. 2003;53:406–11.PubMed
53.
Krampen G. Fragebogen zu Kompetenz-und Kontrollüberzeugungen:(FKK). Hogrefe: Verlag für Psychologie; 1991.
54.
Kemper CJ, Ziegler M, Taylor S. ASI-3-Angstsensitivitätsindex-3; 2022.
55.
Spielberger CD, Gorsuch RL, Lushene RE, Vagg PR, Jacobs GA. State-Trait Anxiety Inventory. Palo Alto: Mind Garden; 1983.
56.
Kennedy RS, Lane NE, Berbaum KS, Lilienthal MG. Simulator sickness questionnaire: an enhanced method for quantifying simulator sickness. Int J Aviation Psychol. 1993;3:203–20.CrossRef
57.
Pedersen AB, Mikkelsen EM, Cronin-Fenton D, Kristensen NR, Pham TM, Pedersen L, et al. Missing data and multiple imputation in clinical epidemiological research. Clin Epidemiol. 2017;9:157.PubMedPubMedCentralCrossRef
58.
Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. Bmj. 2002;325:652–4.PubMedPubMedCentralCrossRef
59.
Haverkamp N, Beauducel A. Violation of the sphericity assumption and its effect on type-I error rates in repeated measures ANOVA and multi-level linear models (MLM). Front Psychol. 2017;8:1841.PubMedPubMedCentralCrossRef
Metadata
Title
Self-guided digital treatment with virtual reality for panic disorder and agoraphobia: a study protocol for a randomized controlled trial
Authors
Jari Planert
Alla Machulska
Anne-Sophie Hildebrand
Kati Roesmann
Esra Otto
Tim Klucken
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06366-x

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue

Research

Minimal effective dose of ultrasound-guided rectus sheath block to reduce oral analgesic requirement after ambulatory laparoscopic tubal resection: a randomized controlled superiority trial

Study protocol

Effect of intraoperative goal-directed fluid therapy on the postoperative brain edema in patients undergoing high-grade glioma resections: a study protocol of randomized control trial

Study protocol

Study protocol: Effects of active versus passive recharge burst spinal cord stimulation on pain experience in persistent spinal pain syndrome type 2: a multicentre randomized trial (BURST-RAP study)

Study protocol

Dimensional changes of peri-implant tissue following immediate flapless implant placement and provisionalization with or without xenograft in the anterior maxilla: a study protocol for a randomized controlled trial

Study protocol

The SMARTscreen Trial: a randomised controlled trial investigating the efficacy of a GP-endorsed narrative SMS to increase participation in the Australian National Bowel Cancer Screening Program

Study protocol

Effect of novel training to normalize altered finger force direction post-stroke: study protocol for a double-blind randomized controlled trial